Pharmacological relationship between nicotinic and opioid systems in analgesia and corticosterone elevation. 2011

Akihiro Yamamoto, and Norikazu Kiguchi, and Yuka Kobayashi, and Takehiko Maeda, and Keiko Ueno, and Chizuko Yamamoto, and Shiroh Kishioka
Department of Pharmacology, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-0012, Japan.

OBJECTIVE Although a pharmacological relationship is known to exist between nicotine and morphine, the exact mechanisms are unclear. Here, we investigated crosstalk between the endogenous opioid system and nicotinic acetylcholine receptors (nAChRs), specifically in nicotine-induced analgesia and activation of the hypothalamic-pituitary-adrenal (HPA) axis. METHODS Nicotine and morphine were administered subcutaneously to mice and the effects of these drugs on analgesia and serum corticosterone (SCS) levels were evaluated by the tail-pinch method and fluorometric assay, respectively. RESULTS Both nicotine and morphine produced analgesia and SCS increase after a single injection. Nicotine-induced analgesia was prevented by both mecamylamine (MEC; 1mg/kg) and naloxone (NLX; 1mg/kg), and also by repeated administration of morphine or nicotine. Morphine-induced analgesia was prevented by NLX, but not MEC, and by repeated administration of morphine, but not nicotine. Conversely, the nicotine-induced increase in SCS level was prevented by MEC, but not NLX. Morphine-induced SCS increase was prevented by NLX, but not MEC. Moreover, nicotine-induced analgesia was suppressed by dihydro-β-erythroidine (DHβE; an antagonist for the α4β2 nAChR) or methyllycaconitine (MLA; an antagonist for the α7 nAChR). The nicotine-induced increase in SCS level was suppressed by DHβE, but not MLA. CONCLUSIONS Nicotine-induced analgesia may involve the endogenous opioid system through crosstalk with nicotinic pathways. However, the relationship between these systems does not extend to cooperative actions in nicotine-induced HPA-axis activation.

UI MeSH Term Description Entries
D007030 Hypothalamo-Hypophyseal System A collection of NEURONS, tracts of NERVE FIBERS, endocrine tissue, and blood vessels in the HYPOTHALAMUS and the PITUITARY GLAND. This hypothalamo-hypophyseal portal circulation provides the mechanism for hypothalamic neuroendocrine (HYPOTHALAMIC HORMONES) regulation of pituitary function and the release of various PITUITARY HORMONES into the systemic circulation to maintain HOMEOSTASIS. Hypothalamic Hypophyseal System,Hypothalamo-Pituitary-Adrenal Axis,Hypophyseal Portal System,Hypothalamic-Pituitary Unit,Hypothalamic Hypophyseal Systems,Hypothalamic Pituitary Unit,Hypothalamo Hypophyseal System,Hypothalamo Pituitary Adrenal Axis,Portal System, Hypophyseal
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D008297 Male Males
D008813 Mice, Inbred ICR An inbred strain of mouse that is used as a general purpose research strain, for therapeutic drug testing, and for the genetic analysis of CARCINOGEN-induced COLON CANCER. Mice, Inbred ICRC,Mice, ICR,Mouse, ICR,Mouse, Inbred ICR,Mouse, Inbred ICRC,ICR Mice,ICR Mice, Inbred,ICR Mouse,ICR Mouse, Inbred,ICRC Mice, Inbred,ICRC Mouse, Inbred,Inbred ICR Mice,Inbred ICR Mouse,Inbred ICRC Mice,Inbred ICRC Mouse
D009020 Morphine The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. Morphine Sulfate,Duramorph,MS Contin,Morphia,Morphine Chloride,Morphine Sulfate (2:1), Anhydrous,Morphine Sulfate (2:1), Pentahydrate,Oramorph SR,SDZ 202-250,SDZ202-250,Chloride, Morphine,Contin, MS,SDZ 202 250,SDZ 202250,SDZ202 250,SDZ202250,Sulfate, Morphine
D009538 Nicotine Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. Nicotine Bitartrate,Nicotine Tartrate
D010146 Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS. Suffering, Physical,Ache,Pain, Burning,Pain, Crushing,Pain, Migratory,Pain, Radiating,Pain, Splitting,Aches,Burning Pain,Burning Pains,Crushing Pain,Crushing Pains,Migratory Pain,Migratory Pains,Pains, Burning,Pains, Crushing,Pains, Migratory,Pains, Radiating,Pains, Splitting,Physical Suffering,Physical Sufferings,Radiating Pain,Radiating Pains,Splitting Pain,Splitting Pains,Sufferings, Physical
D010913 Pituitary-Adrenal System The interactions between the anterior pituitary and adrenal glands, in which corticotropin (ACTH) stimulates the adrenal cortex and adrenal cortical hormones suppress the production of corticotropin by the anterior pituitary. Pituitary Adrenal System,Pituitary-Adrenal Systems,System, Pituitary-Adrenal,Systems, Pituitary-Adrenal
D003345 Corticosterone An adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid. (From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437)
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal

Related Publications

Akihiro Yamamoto, and Norikazu Kiguchi, and Yuka Kobayashi, and Takehiko Maeda, and Keiko Ueno, and Chizuko Yamamoto, and Shiroh Kishioka
January 1984, Proceedings of the Western Pharmacology Society,
Akihiro Yamamoto, and Norikazu Kiguchi, and Yuka Kobayashi, and Takehiko Maeda, and Keiko Ueno, and Chizuko Yamamoto, and Shiroh Kishioka
January 1993, Klinicheskaia laboratornaia diagnostika,
Akihiro Yamamoto, and Norikazu Kiguchi, and Yuka Kobayashi, and Takehiko Maeda, and Keiko Ueno, and Chizuko Yamamoto, and Shiroh Kishioka
November 1991, British journal of anaesthesia,
Akihiro Yamamoto, and Norikazu Kiguchi, and Yuka Kobayashi, and Takehiko Maeda, and Keiko Ueno, and Chizuko Yamamoto, and Shiroh Kishioka
March 1982, Science (New York, N.Y.),
Akihiro Yamamoto, and Norikazu Kiguchi, and Yuka Kobayashi, and Takehiko Maeda, and Keiko Ueno, and Chizuko Yamamoto, and Shiroh Kishioka
May 1984, The Journal of pharmacy and pharmacology,
Akihiro Yamamoto, and Norikazu Kiguchi, and Yuka Kobayashi, and Takehiko Maeda, and Keiko Ueno, and Chizuko Yamamoto, and Shiroh Kishioka
September 1985, Neurological research,
Akihiro Yamamoto, and Norikazu Kiguchi, and Yuka Kobayashi, and Takehiko Maeda, and Keiko Ueno, and Chizuko Yamamoto, and Shiroh Kishioka
July 2008, Journal of gastroenterology and hepatology,
Akihiro Yamamoto, and Norikazu Kiguchi, and Yuka Kobayashi, and Takehiko Maeda, and Keiko Ueno, and Chizuko Yamamoto, and Shiroh Kishioka
January 2002, CNS drugs,
Akihiro Yamamoto, and Norikazu Kiguchi, and Yuka Kobayashi, and Takehiko Maeda, and Keiko Ueno, and Chizuko Yamamoto, and Shiroh Kishioka
October 1991, Behavioral neuroscience,
Akihiro Yamamoto, and Norikazu Kiguchi, and Yuka Kobayashi, and Takehiko Maeda, and Keiko Ueno, and Chizuko Yamamoto, and Shiroh Kishioka
February 2008, Anesthesia and analgesia,
Copied contents to your clipboard!